Samuel H. Masters
University of Washington
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Samuel H. Masters.
JAMA | 2014
Harsha Thirumurthy; Samuel H. Masters; Samwel Rao; Megan A. Bronson; Michele Lanham; Eunice Omanga; Emily Evens; Kawango Agot
IMPORTANCE Novel strategies are needed to increase the uptake of voluntary medical male circumcision (VMMC) in sub-Saharan Africa and enhance the effectiveness of male circumcision as an HIV prevention strategy. OBJECTIVE To determine whether small economic incentives could increase circumcision prevalence by addressing reported economic barriers to VMMC and behavioral factors such as present-biased decision making. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted between June 22, 2013, and February 4, 2014, among 1504 uncircumcised men aged 25 to 49 years in Nyanza region, Kenya. VMMC services were provided free of charge and participants were randomized to 1 of 3 intervention groups or a control group. INTERVENTIONS Participants in the 3 intervention groups received varying amounts of compensation conditional on undergoing circumcision at 1 of 9 study clinics within 2 months of enrollment. Compensation took the form of food vouchers worth 200 Kenya shillings (≈ US
Social Science & Medicine | 2013
Samuel H. Masters; Roy Burstein; George Amofah; Patrick Abaogye; Santosh Kumar; Michael Hanlon
2.50), 700 Kenya shillings (≈ US
The Lancet HIV | 2016
Harsha Thirumurthy; Samuel H. Masters; Sue Napierala Mavedzenge; Suzanne Maman; Eunice Omanga; Kawango Agot
8.75), or 1200 Kenya shillings (≈ US
PLOS Medicine | 2016
Samuel H. Masters; Kawango Agot; Beatrice Obonyo; Sue Napierala Mavedzenge; Suzanne Maman; Harsha Thirumurthy
15.00), which reflected a portion of transportation costs and lost wages associated with getting circumcised. The control group received no compensation. MAIN OUTCOMES AND MEASURES VMMC uptake within 2 months. RESULTS Analysis of data for 1502 participants with complete data showed that VMMC uptake within 2 months was higher in the US
BMJ Open | 2015
Emily Dansereau; Felix Masiye; Emmanuela Gakidou; Samuel H. Masters; Roy Burstein; Santosh Kumar
8.75 group (6.6%; 95% CI, 4.3%-9.5% [25 of 381]) and the US
Journal of Acquired Immune Deficiency Syndromes | 2016
Harsha Thirumurthy; Samuel H. Masters; Samwel Rao; Kate Murray; Ram Prasad; Joshua Graff Zivin; Eunice Omanga; Kawango Agot
15.00 group (9.0%; 95% CI, 6.3%-12.4% [34 of 377]) than in the US
PLOS ONE | 2014
Samuel H. Masters; Roy Burstein; Brendan DeCenso; Kelsey Moore; Annie Haakenstad; Gloria Ikilezi; Jane Achan; Ivy Osei; Bertha Garshong; Caroline Kisia; Pamela Njuguna; Joseph B. Babigumira; Santosh Kumar; Michael Hanlon; Emmanuela Gakidou
2.50 group (1.9%; 95% CI, 0.8%-3.8% [7 of 374]) and the control group (1.6%; 95% CI, 0.6%-3.5% [6 of 370]). In logistic regression analysis, the US
BMC Health Services Research | 2012
Michael Hanlon; Roy Burstein; Samuel H. Masters; Raymond Zhang
8.75 group had significantly higher VMMC uptake than the control group (adjusted odds ratio [AOR] 4.3; 95% CI, 1.7-10.7), as did the US
PLOS ONE | 2015
Herbert C. Duber; Emily Dansereau; Samuel H. Masters; Jane Achan; Roy Burstein; Brendan DeCenso; Anne Gasasira; Gloria Ikilezi; Caroline Kisia; Felix Masiye; Pamela Njuguna; Thomas A. Odeny; Emelda A. Okiro; D. Allen Roberts; Emmanuela Gakidou
15.00 group (AOR 6.2; 95% CI, 2.6-15.0). Effect sizes for the US
PLOS ONE | 2015
Emily Dansereau; Emmanuela Gakidou; Marie Ng; Jane Achan; Roy Burstein; Brendan DeCenso; Anne Gasasira; Gloria Ikilezi; Caroline Kisia; Samuel H. Masters; Pamela Njuguna; Thomas A. Odeny; Emelda A. Okiro; D. Allen Roberts; Herbert C. Duber
8.75 and US